Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Releases
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Estrogen Shrinks Some Breast Tumors
Uncategorized

Estrogen Shrinks Some Breast Tumors

By medwebNov 1, 2003
Share
Facebook Twitter Email

November 11, 2003

Estrogen Shrinks Some Breast Tumors

CHICAGO— Striking, paradoxical discoveries by Feinberg School of Medicine researchers suggest that low levels of estrogen—the same hormone that promotes breast cancer in its early stages—can shrink breast tumors that have developed resistance to the drugs tamoxifen and raloxifene.

The findings are described in two studies by V. Craig Jordan, PhD, and co-researchers at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University that were published in the Nov. 5 issue of the Journal of the National Cancer Institute.

Dr. Jordan is the Diana, Princess of Wales, Professor of Cancer Research; professor of molecular pharmacology and biological chemistry at the medical school; and director of the Lynn Sage Breast Cancer Research Program at the Cancer Center.

Tamoxifen is a selective estrogen receptor modulator (SERM) used to treat estrogen receptor-positive breast cancers and prevent recurrence of the disease. However, tamoxifen loses effectiveness after five years and can subsequently stimulate breast cancer growth. New endocrine therapies, such as aromatase inhibitors and the antiestrogen fulvestrant, are used to boost the effects of tamoxifen, although some studies suggest that low levels of estrogen may also inhibit the growth of tamoxifen-stimulated breast tumors.

Clodia Osipo, PhD, who is lead author on the tamoxifen article; Dr. Jordan; and Cancer Center colleagues examined the effect of tamoxifen, the estrogen estradiol, and fulvestrant, both alone and in various combinations, in a laboratory model of tamoxifen-stimulated human breast cancer.

The researchers found that low levels of estradiol caused tamoxifen-resistant breast tumors to regress, apparently by increasing cell suicide, or apoptosis, through decreased expression of the antiapoptotic factors Her2/neu and NF-(kappa)B and increased expression of the death receptor protein Fas, with regulates apoptosis.

Combined treatment with fulvestrant plus estadiol unexpectedly promoted the growth of tamoxifen-stimulated breast tumors, suggesting that use of fulvestrant in patients with sufficient levels of circulating estrogen may actually stimulate tumor growth.

In the second study, Hong Liu, MD, PhD; Dr. Jordan, and cancer center co-researchers examined whether low doses of estradiol would also have an effect on raloxifene-resistant breast cancer cells. Widespread use of the SERM raloxifene for the prevention of osteoporosis has raised concerns that such women may develop breast cancers that are resistant to raloxifene.

Treatment of cultured raloxifene-resistant breast cancer cells with estradiol for 12 to 24 days inhibited cell growth compared with untreated control cells. Estradiol treatment also caused a decrease in NF-(kappa)B activity, an increase in the expression of the Fas protein, and an increase in apoptosis.

The researchers also found that raloxifene-resistant cells were also resistant to tamoxifen, suggesting that tamoxifen would not be effective against breast cancers that are resistant to raloxifene. In addition, mice with drug-resistant tumors experienced tumor shrinkage after five weeks of estradiol treatment.

Together, these studies “suggest that it is possible for a patient’s own estrogen to act as an anticancer agent in SERM-resistant breast cancers,” Dr. Jordan said.

“Clearly, a clinical strategy to use an aromatase inhibitor after SERM resistance may have some short-term benefit for patients, but it is possible that a novel strategy of briefly treating women with estrogen before re-instituting estrogen-deprivation therapy may benefit certain women,” he said.

Share. Facebook Twitter Email

Related Posts

Lurie Cancer Center Receives Merit Extension from NCI

Oct 20, 2021

Drug Combination May Reduce Risk of Leukemia Relapse

Mar 26, 2020

Rewriting the Role of a Transcription Factor

Mar 19, 2020

Comments are closed.

Latest News

Sex-Specific Mechanisms for Major Depressive Disorder Identified in Response to Dysregulated Stress Hormones

Mar 23, 2023

Pre-Surgery Immunotherapy May Increase Survival in Advanced Melanoma

Mar 23, 2023

Hormone Therapy Plus Current Treatments Improves Survival in Prostate Cancer

Mar 22, 2023

How ChatGPT Has, and Will Continue to, Transform Scientific Research

Mar 21, 2023

New Directions for HIV Treatment

Mar 21, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20230317_NM651
20230317_NM610
20230317_NM569
20230317_NM537
20230317_NM331
20230317_NM323
20230317_NM316
20230317_NM336
20230317_NM626
20230317_NM662
20230317_NM655
20230317_NM642

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.